title: [Cost-effectiveness of the HIV screening program carried out in Guangxi Zhuang Autonomous Region infectious disease special demonstration project areas].
abstract: OBJECTIVE
  To analyze the cost effectiveness of HIV screening project in three Guangxi infectious disease special demonstration project countries in 2013.
  
  
  METHODS
  To calculate the funds used for the HIV screening project and to study the data on HIV/AIDS and HAART. A five-tree markov model was used to evaluate the quality adjusted life year (QALY) of this HIV screening project and to analyze the related cost effectiveness of the project.
  
  
  RESULTS
  The cost of HIV screening in Guangxi infectious disease special demonstration project areas was 19.205 million Yuan and having identified 1 218 HIV/AIDS patients. The average costs for HIV/AIDS positive detection in three project countries were 14.562, 18.424 and 14.042 thousand Yuan per case. The QALYs gained from finding a HIV/AIDS case were 12.736, 8.523 and 8.321 on average, with the total number of QALYs gained from the project as 5 973.184, 3 613.752 and 2 704.325. The overall cost effectiveness ratio of the project was 1.562 thousand Yuan per QALY, and 1.143, 2.162 and 1.688 thousand Yuan per QALY in these three project countries. Project country "A" showed better cost effectiveness index than country B and C.
  
  
  CONCLUSIONS
  The HIV screening project in Guangxi seemed relatively cost-effective but the average cost of HIV/AIDS positive detection was expensive. To strengthen HAART work for HIV/AIDS could improve the cost-effective of the project.
authors.affiliation: Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning 530028, China.
authors.forename: Huaxiang
authors.initials: H
authors.lastname: Lu
authors.affiliation: Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning 530028, China.
authors.forename: Liuhong
authors.initials: L
authors.lastname: Luo
authors.affiliation: Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning 530028, China.
authors.forename: Li
authors.initials: L
authors.lastname: Chen
authors.affiliation: Binyang Center for Disease Control and Prevention.
authors.forename: Shizhen
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Luzhai Center for Disease Control and Prevention.
authors.forename: Yingfang
authors.initials: Y
authors.lastname: Liang
authors.affiliation: Qintang Center for Disease Control and Prevention.
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.affiliation: Luzhai Center for Disease Control and Prevention.
authors.forename: Zhenqiang
authors.initials: Z
authors.lastname: Chen
authors.affiliation: Binyang Center for Disease Control and Prevention.
authors.forename: Xiaoxing
authors.initials: X
authors.lastname: Huo
authors.affiliation: Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning 530028, China; Email: maxpeon@hotmail.com.
authors.forename: Xinghua
authors.initials: X
authors.lastname: Wu
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D002681:China; D003362:Cost-Benefit Analysis; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D008403:Mass Screening / Q000191:economics*; D015397:Program Evaluation; D019057:Quality-Adjusted Life Years